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Think outside the (SOCS) box.

ABSTRACT 
Mycobacterium tuberculosis is the world’s most successful bacterial killer. 
During infection, mycobacteria reside inside host cells encapsulated within a 
granuloma structure in the latent, asymptomatic phase of infection. Only 10% of 
latently infected develop active, infectious tuberculosis months or years after the initial 
infection. The mechanisms that determine latency and bacterial control as well as 
protection during active tuberculosis are still not fully understood. Members of the 
SOCS protein family are regulators of cytokine signaling via inhibition of JAK-STAT 
activation and their expression is increased during different kinds of infections. 
Therefore, the purpose of this thesis was to study the role of SOCS1, SOCS2 and 
SOCS3 during mycobacterial infections. 
We demonstrated that infection with M. tuberculosis in vitro and in mice 
strongly upregulated SOCS1 expression. Interestingly, SOCS1 reduced IFN-γ secretion 
by macrophages in response to IL-12 rather than responses to IFN-γ itself. In line, 
SOCS1-deficient macrophages showed improved growth control of mycobacteria in 
vitro. Furthermore, in a mouse model of infection, we demonstrated that SOCS1 
expression by macrophages impaired bacterial clearance before the onset of protective 
adaptive immune responses. However, SOCS1 did not hamper adaptive immune-
controlled bactericidal mechanisms at later time points. At this stage of infection, 
SOCS1 expression by non-macrophage cells protected mice from severe 
immunopathology. 
 Additionally, we showed that SOCS2 expression was induced in an IRF3-
dependent manner after infection with M. bovis BCG or incubation with LPS in vitro. 
However, SOCS2-deficient and control mice infected with M. tuberculosis displayed 
similar bacterial burdens in the lungs. 
 In studying the role of SOCS3 in different mouse models, we found that the lack 
of SOCS3 in either myeloid or T cells dramatically increased susceptibility to M. 
tuberculosis infection. During infection, SOCS3 expression in macrophages and 
dendritic cells was required to prevent an inhibitory effect of IL-6 on TNF and IL-12 
secretion and elevated IFN-γ expression by CD4+ T cells. More detailed studies 
revealed that the lack of SOCS3 in myeloid cells could be mimicked by mutating the 
SOCS3 binding site of the gp130 receptor. This indicates that among the receptors, 
which can be regulated by SOCS3, the control over the IL-6 family gp130 receptor is 
fundamental for proper immune responses. Surprisingly, mice bearing SOCS3-deficient 
T cells were not susceptible to BCG infection. Moreover, a proper defense against 
challenge with M. tuberculosis infection was restored if mice deficient for SOCS3 in T 
cells had been BCG-vaccinated. 
In conclusion, we demonstrated a pivotal role of SOCS1 and SOCS3 on the 
outcome of infection with M. tuberculosis. SOCS1 expression allows fast bacterial 
growth during the early phase of infection and protects from severe inflammation 
during later stages. SOCS3 expression in myeloid and T cells independently mediates 
resistance to M. tuberculosis infection by modulating T cell functions. Based on the 
obtained data, we suggest that SOCS3-regulated pathways are promising targets for 
future therapies as well as vaccination strategies. 
POPULAR SCIENCE SUMMARY 
  
Tuberculosis is a long known infectious disease that continues to cause 1.5 
million deaths every year. Although treatment is available, it is long lasting and the 
numbers of antibiotic-resistant cases are increasing. Moreover, the available vaccine is 
not efficient in adults. To combat tuberculosis, more knowledge about how the immune 
system can protect against M. tuberculosis is required. Members of the SOCS protein 
family have important functions in the inhibition of immune signaling pathways. Since 
proper regulation and balance of immune responses during mycobacterial infections is 
crucial for infection control, we investigated the role of SOCS1, SOCS2 and SOCS3 
during M. tuberculosis infection. 
 We chose mice as the animal model of infection for our studies. In order to 
investigate the role of the different SOCS molecules during mycobacterial infections, 
we took advantage of mice lacking these specific proteins and compared their outcome 
of infection with infected control mice.  
 Regarding the function of SOCS1 in M. tuberculosis-infected mice, we found 
that SOCS1 impaired early immune activation leading to increased bacterial numbers in 
the lungs. However, presence of SOCS1 was beneficial for the infected host restricting 
infection-induced inflammation at later time points. 
 For SOCS2, we demonstrated that SOCS2 expression was upregulated in 
mycobacteria-infected macrophages, but SOCS2-deficient mice did not show increased 
susceptibility to M. tuberculosis infection. 
 Furthermore, we studied the role of SOCS3 in different immune cells, which are 
known to be important during M. tuberculosis infection. We found that the lack of 
SOCS3 in myeloid cells, which belong to the first line of defense, as well as in T cells, 
which belong to the adaptive immunity as second line of defense, dramatically 
increased susceptibility to M. tuberculosis infections. Interestingly, if mice deficient for 
SOCS3 in T cells were vaccinated with the attenuated M. bovis strain BCG before M. 
tuberculosis infection, they could control M. tuberculosis infection equally well as mice 
expressing SOCS3.  
 Summarizing, we illustrated a role for SOCS1 and SOCS3 during mycobacterial 
infections, whereas the function of SOCS2 was shown to be minor or redundant. 
SOCS1 improves bacterial growth during the early phase of infection and protects from 
severe inflammation during later stages. SOCS3 expression in myeloid and T cells is 
required to mediate resistance to M. tuberculosis infection. This makes SOCS3-
regulated pathways promising targets for future therapies and suggests that their 
modulation may improve vaccination as well as the control of mycobacterial infections. 
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1 INTRODUCTION 
1.1 MYCOBACTERIUM TUBERCULOSIS 
Mycobacterium tuberculosis is the causative agent of the infectious disease 
tuberculosis1. It is estimated that around one third of the global population is 
currently infected with M. tuberculosis, but the probability of those infected to 
develop active tuberculosis during their lifetime is only around 10%2. Prediction for 
onset of clinical disease is difficult as critical biomarkers in infected but healthy 
individuals are not available3. However, the risk of developing active tuberculosis 
increases to 10% per year if a co-infection with the human immunodeficiency virus 
(HIV) and M. tuberculosis occurs4, suggesting that immune responses are responsible 
for the asymptomatic infection. In 2010, the World Health Organization (WHO) 
reported for tuberculosis an incidence of over 8 million people and 1.2-1.5 million 
deaths (including deaths from tuberculosis among HIV-positive patients) making 
tuberculosis the second leading cause of death from an infectious disease worldwide, 
after HIV5. Other immune suppressive conditions such as diabetes, alcoholism, 
smoking, advanced age and malnutrition are known to promote disease6,7. However, a 
detailed understanding of why reactivation of M. tuberculosis occurs in some 
individuals has yet to be determined.  
The treatment regiment for tuberculosis with combined antibiotics is long, but 
efficient when followed properly. Due to insufficient drug treatment, drug-resistant 
M. tuberculosis strains have developed over the last decades, including strains 
resistant to isoniazid and rifampicin, the standard treatment antibiotics, as well as 
extensively drug-resistant strains that additionally resist treatment with one 
fluoroquinolone or injectable second-line drug5,8.  
The only available vaccine against tuberculosis is the attenuated 
Mycobacterium bovis Bacille Calmette Guérin (BCG) that was first introduced in 
1921. BCG is one of the most used vaccines worldwide, but protection to 
tuberculosis, especially in adults, varies from 0% to 80%9-11. Moreover, BCG 
vaccination does not provide sterilizing immunity that is needed to prevent the 
establishment of a latent persistent M. tuberculosis infection or active pulmonary 
tuberculosis. However, over the last years several new tuberculosis vaccines have 
reached phase I clinical trials12. 
Mycobacteria are non-motile rods of 2-4 micrometers length. Due to the high 
lipid content of its cell wall, M. tuberculosis cannot be classified as Gram-positive or 
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Gram-negative, but it can be identified via acid fast staining (Ziehl-Neelsen stain). 
The cell wall consists of peptidogycans and complex lipids, where the major lipid 
components are mycolic acid, cord factor and wax-D. Different compositions of the 
cell wall can contribute to the virulence of different mycobacteria strains13. M. 
tuberculosis is an obligate aerobe and a facultative intracellular pathogen, and it 
usually infects myeloid cells. M. tuberculosis has a slow growing rate with a doubling 
time of 18 to 24 hours, so that cultures of clinical specimens must be held for 6-8 
weeks, which makes diagnostics difficult.  
 
1.1.1 Experimental models of M. tuberculosis  
As M. tuberculosis has a very limited host range with no known natural hosts 
beyond humans14, alternative models to study the disease have been tested. Based on 
the infection of phagocytes by M. tuberculosis, cell cultures of primary murine 
macrophages, human monocyte-derived macrophages and dendritic cells, have been 
applied to investigate pathogen-host interactions on intracellular and cellular levels15.   
The first animal model, the guinea pig, was used by Robert Koch when he 
identified M. tuberculosis as the causative agent of tuberculosis in 18821. Guinea pigs 
show clinical symptoms around 30 days after infection and survive for 100-140 
days16,17. Importantly, lung responses to mycobacterial stimuli in guinea pigs are 
similar to human responses, even leading to the development of  primary pulmonary 
granulomas, which closely resemble human granulomas17-19. The hallmark of human 
granulomas, necrotic centers, are found in infected guinea pigs making them a 
valuable model to test efficacy of tuberculosis vaccines and anti-mycobacterial 
drugs20,21. 
Mice are the most widely used experimental animal model today due to their 
lower overhead costs as compared to monkeys or guinea pigs, as well as their high 
reproductive rate, the availability of reagents to characterize mouse responses and 
established methods for manipulation of gene expression with knockout, conditional 
knockdown and transgenic mice. The infection of mice is performed either 
intravenously, intranasally or via aerosol, the latter mimics the natural infection route 
in humans. A major drawback of the mouse model is the relatively small protective 
effect of BCG vaccination that reduces bacteria loads after M. tuberculosis challenge 
around 1 log, in comparison to the 2-3 logs reduction seen in guinea pigs21. 
Furthermore, the formed granulomas in infected mice are not highly structured; 
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consisting of cellular infiltrations with irregular borders, whereas a central necrosis 
and caseation, as found in human tuberculosis, is absent22.  
Mycobacteria in aerosol-infected mice replicate progressively in the lungs 
during the first 3 weeks after infection (Fig. 1)23. The onset of adaptive immune 
responses slows down the bacterial growth, reduces bacteria levels approximately 1 
log, and after 4-5 weeks of infection, bacterial levels reach a level that will remain 
constant throughout the infection  (Fig. 1)24.  
Tuberculosis is typically manifested in the lungs but can also affect other 
sites, described as extra-pulmonary tuberculosis. In mice, bacterial dissemination to 
other organs such as the draining lymph node, spleen and liver can be detected after 
10 days of aerosol infection25. Depending on the initial dose and genetic background 
of infected mice, they may survive for longer than 200 days, but since all mice 
develop active disease, they do not provide a model to study latency26.  
One experimental option to mimic latency in mice is the treatment of M. 
tuberculosis-infected mice with anti-mycobacterial drugs to reduce the bacterial load 
to undetectable levels followed by either spontaneous or induced reactivation of 
infection27,28. However, it is difficult to evaluate how well this model reflects M. 
tuberculosis latency in humans. 
 
Figure 1: Kinetic of colony forming units (CFU) of M. tuberculosis in lungs of 
aerosol-infected mice (adapted from 29). 
Mycobacteria replicate progressively in the lungs during the first 3 weeks of 
infection, bacterial numbers peak after around 4 weeks and stay at a plateau for more 
than 10 weeks. 
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The outcome of infection in cynomolgus macaques displays strong similarities 
with human disease progression.  After a low dose infection some primates generate 
latent infections, an important stage of M. tuberculosis infection that cannot be 
investigated in the commonly used mouse model30.  
 
1.1.2 Transmission of M. tuberculosis 
When infected humans with active pulmonary tuberculosis cough or sneeze, 
they can spread infectious droplets that are required for transmission of M. 
tuberculosis. Infection occurs if inhaled droplets of bacilli reach the alveoli of the 
lungs. Exhaled droplets or nuclei are known to remain in the atmosphere for several 
hours and the infectious dose is low, probably under 10 bacteria31.  
 
1.1.3 Innate immune responses 
The first contact between inhaled mycobacteria and the host is the uptake of 
M. tuberculosis by resident alveolar macrophages within the airways. The ingested 
mycobacteria are often destroyed directly depending on the mycobactericidal 
capacities of the host phagocyte and the virulence of the mycobacterium. Pathogenic 
mycobacteria replicate in the phagosome of the primary host cell and successfully 
prevent fusion of the phagosome with late endosome/lysosome organelles32,33. 
Moreover, virulent mycobacteria were shown to escape from the lysosomes into the 
cytosol34. Phagocytosis of mycobacteria can be mediated by several receptors such as 
complement, mannose and scavenger receptors35-37. The binding of M. tuberculosis 
molecules to various pattern recognition receptors stimulates the activation of innate 
immune responses in the host. For M. tuberculosis, recognition mainly by toll-like 
receptor (TLR) 2, 4 and 9 and subsequent activation of MyD88 and TRIF-dependent 
pathways has been described38-42. This innate immune activation leads to up-
regulation of co-stimulatory molecules and production of cytokines by infected 
phagocytes. In addition to macrophages, dendritic cells and neutrophils can also be 
infected with M. tuberculosis43. However, innate immune mechanisms are not 
sufficient to control mycobacterial growth, so that adaptive immune responses need 
to be activated as a support. Infected dendritic cells migrate to the draining lymph 
nodes to activate naïve T cells, whereas macrophages recruit immune cells to the site 
of infection by secretion of attractant chemokines24. The following steps are required 
for a successful protective immune response to M. tuberculosis: (1) activation of 
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antigen-specific effector T cells that migrate back to the lung to activate infected 
macrophages and (2) the formation of granulomas. 
 
1.1.4 Adaptive immune responses 
Antigen-specific CD4+ and CD8+ T cells were shown to be required for the 
control of M. tuberculosis infection44-46. This is especially apparent in HIV patients, 
in which a decline of CD4+ T cells coincides with tuberculosis disease progression47. 
Moreover, deficiency of these cell populations increased susceptibility in murine 
models of the acute and chronic infection48,49. Dissecting the role of T cell subsets in 
mice demonstrated that the control of M. tuberculosis infection was to a greater 
extent dependent on CD4+ than on CD8+ T cells46.  
IL-12 produced by dendritic cells is crucial for the initiation of the adaptive 
immune response and stimulates the development of the CD4+ T cell subpopulation 
Th1 in response to M. tuberculosis infection. The importance of IFN-γ-secreting Th1 
cells during M. tuberculosis infection is well established in mice and humans50-53. 
Moreover, lack of IFN-γ as well as the Th1 specific transcription factor Tbet, 
increases susceptibility to M. tuberculosis infection in mice50,54. 
IFN-γ produced by Th1 cells during M. tuberculosis infection counteracts the 
generation of Th17 cells and thereby regulates the balance between Th1 and Th17 
cells55. Th17 cells are characterized by the secretion of IL-17 and the expression of 
RORγ transcription factor,56 and have been shown to be induced during M. 
tuberculosis infection57.  
Interestingly, the onset of adaptive immune responses after M. tuberculosis 
infection via aerosol is delayed in comparison to other pathogens. In the mouse 
model, the arrival of antigen-specific T cells into the lung associated with 
mycobacterial growth restriction, typically occurs 3 to 4 weeks after infection. 
Studies using transgenic mice that express T cell receptors specific for mycobacterial 
antigens suggested two time limiting steps: (1) the arrival of infected dendritic cells in 
the draining lymph node and (2) a threshold of around 1500 mycobacteria in the 
lymph node that are required for naïve antigen-specific T cells activation24. Studies 
comparing relatively resistant to more susceptible mouse strains showed that bacteria 
in resistant mouse strains appeared earlier in draining lymph node and could therefore 
sooner mount an antigen-specific T cell response 25. 
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The induction of pathogen-specific regulatory T  cells (Tregs) may contribute 
to the delay of T cell responses during M. tuberculosis infection. In humans and mice, 
regulatory T cells were found to expand and accumulate at the site of infection58-61. 
Regulatory T cells, characterized by expression of transcription factor foxp3 and 
surface markers CD4 and CD25, are important to down-regulate immune activation 
to prevent autoimmune diseases62, but their role during tuberculosis infection is under 
debate. On the one hand, transfer of M. tuberculosis-specific T regs in mice resulted 
in increased bacterial burdens in the lungs, whereas others reported an only transient 
reduction of bacterial loads after depletion of CD25+ T cells63,64.  
 
1.1.5 Granuloma formation 
The hallmark of tuberculosis and other diseases, the granuloma, typically 
consists of a core of infected macrophages or epithelioid cells, and giant cells 
surrounded by foamy macrophages and other mononuclear phagocytes encircled by a 
mantle of lymphocytes. Mature granulomas are further encapsulated by collagen 
fibers. The initiation of a stable granuloma during a subclinical stage of infection 
leads to containment of the mycobacteria and thus is considered to be a host-
protective structure65,66. This exclusive perspective is questioned by recent findings 
suggesting granulomas as a niche, in which the mycobacterium can grow and 
persist67. The environment of the granuloma is believed to respond to mycobacteria, 
and mycobacterial antigens were shown to be required for the granuloma formation68. 
Mycobacteria-infected macrophages undergo necrosis, resulting in a caseous center of 
the lesion that is characterized by low oxygen, pH and nutrient levels69. The 
replication of mycobacteria is reduced, and bacteria differentiate into a latent stage, 
but are not eradicated69,70. Yet, in less immune-competent or immune-compromised 
individuals, the fibrous walls lose their integrity, allowing the bacteria to reach the 
bronchi (transmission of infection) or the blood vessels (dissemination of infection). 
Tuberculosis can be manifested in almost any organ, but it occurs most frequently in 
the lungs and lymph nodes, or as generalized lesions resulting from haematogenous 
dissemination. Cases of genital, skin, meningeal, bone and hepatic tuberculosis are 
frequent in highly endemic countries71.  
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1.2 CYTOKINES 
Cytokines are usually soluble protein messengers that coordinate the 
development and function of immune cells, and therefore are indispensable for the 
initiation, maintenance and termination of immune responses72. The group of 
cytokines includes interleukins and other cell signal molecules, such as tumor 
necrosis factor and interferons, which are secreted by activated cells to trigger 
inflammation and respond to infections73. Cytokines have a short half-life; acting in 
either an autocrine or paracrine fashion. Their mode of action is regarded as pro- or 
anti-inflammatory, depending on the change of activation status of the target cell. The 
balance of pro- and anti-inflammatory cytokines is an important mechanism to 
modulate the effect of immune responses: excess of anti-inflammatory cytokines can 
suppress immune activation, whereas excess of pro-inflammatory cytokines can 
create harmful immunopathology.  
Cytokines exert their function by binding to specific cytokine receptors that can 
be either membrane bound or soluble, which need to bind to co-receptors on the 
target cell73. 
Cytokine receptors can be divided in different groups regarding structural 
homologies: type I and II cytokine receptors, TNF receptors, IL-1 family receptors, 
seven transmembrane receptors and G-protein-coupled receptors73. Type I and type II 
cytokine receptors do not possess an intrinsic cytoplasmic kinase activity and 
therefore are dependent on associated Janus kinases (JAKs) to mediate intracellular 
signaling after cytokine binding74. Binding of cytokines to their type I or II receptor 
chain leads to the formation of active receptor heterodimers (or cluster of 
heterodimers) and activation of associated JAKs, which cross-phosphorylate 
themselves and phosphorylate the cytokine receptor creating binding sites for the SH2 
domain of the transcription factors "signal transducers and activators of transcription” 
(STATs)74. Recruited STATs are in turn phosphorylated by the adjacent JAKs and act 
as binding sites for the SH2 domain of another STAT, which also will be 
phosphorylated. The phosphorylated STAT dimer is released from the cytokine 
receptor and translocates into the nucleus where it acts as a transcription activator of 
specific target genes (Fig. 2). The specificity of the intracellular pathways is due to 
the presence of 7 different STAT molecules, activated by different receptors75. 
Moreover, STATs can form homo- or heterodimers depending on the activated 
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receptor, which increases the diversity of target promoters and thereby of gene 
patterns that can be activated. 
 
Figure 2: JAK-STAT pathway mediates responses to cytokines. 
Binding of cytokines to their receptors leads to activation of the associated JAKs. 
Thereafter, STAT molecules get recruited to the receptor and are phosphorylated 
resulting in activated STAT dimers that act as transcription factors in the nucleus. 
 
A tight regulation of cytokine functions is crucial for both the control of 
infections and the prevention of infection-associated immunopathology. Different 
intracellular mechanisms of cytokine signal inhibition are involved in the regulation 
of innate and adaptive immune responses. The JAK-STAT pathway can be negatively 
regulated at different stages: protein tyrosine phosphatases remove phosphates from 
cytokine receptors and activated STATs, SOCS proteins inhibit STAT activation and 
label cytokine receptors for degradation, whereas PIAS (protein inhibitors of 
activated STATs) act in the nucleus76-79. The role of several of these molecules in the 
control of infection and disease is not completely understood.  
 
1.2.1 Tumor necrosis factor  
Tumor necrosis factor (TNF, formerly TNF-α) is a pro-inflammatory cytokine, 
mainly produced by activated mononuclear phagocytes, but also by antigen-
stimulated T cells and mast cells80. TNF is a typical mediator of acute inflammatory 
responses, sepsis, cachexia and can cause fever but also systemic complications 
leading to septic shock81. During infections, TNF is an important early cytokine that 
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recruits neutrophils and granulocytes to the site of infection and evokes microbicidal 
activities in macrophages and neutrophils80.  
TNF plays a diversified role during M. tuberculosis infection contributing to 
the control of mycobacterial growth as well as to the immunopathology as it 
participates in granuloma formation. Genetic deletion and neutralization of TNF in 
mice led to increased bacterial burden and lethality after M. tuberculosis 
infection82,83. Furthermore, patients receiving anti-TNF therapy (used for treatment of 
immune disorders as rheumatoid arthritis) showed an increased rate of reactivation of 
latent tuberculosis84. Similarly in mice, TNF was found to be essential to prevent 
reactivation in a model of latent M. tuberculosis infection85-87.  
As TNF-deficient mice displayed decreased or disorganized granulomas after 
mycobacteria infection, part of its protective role could be assigned to its influence on 
granuloma formation and maintenance82,86,88-91. Accordingly, TNF modulates the 
expression of the chemokines by M. tuberculosis-infected macrophages that recruit 
effector T cells, monocytes and macrophages to the site of infection90,92,93. 
Neutralization of TNF in a chronic infection, when granulomas were already formed, 
disorganized existing granulomas and aberrant pathology was observed87. However, 
the exact mechanisms for how TNF contributes to the control of mycobacterial 
growth are poorly understood and recent data in the zebrafish model showed that 
granuloma formation in M. marinum infection may be independent of TNF94.  
 
1.2.2 Interleukin-12 
Interleukin-12 (IL-12) is an important initiator of adaptive immune responses 
promoting differentiation of naïve CD4+ T cells to Th1 cells, which produce IFN-γ 
and augment cell-mediated immune responses. Bioactive IL-12 (IL-12p70) is 
composed of two covalently linked subunits, p35 and p40, that bind to the receptor 
subunits IL-12Rβ2 and β195. Binding of IL-12 to the receptor leads to activation of 
the Janus kinases JAK2 and TYK2, mediating phosphorylation and activation of the 
transcription factor STAT4 (Fig. 3)95. 
The role for IL-12 during M. tuberculosis infection was highlighted by the 
discovery that deficiencies for IL-12p40 and IL-12Rβ1 can lead to “mendelian 
susceptibility to mycobacterial disease” (MSMD) due to non virulent mycobacteria96. 
Moreover, mice lacking IL-12p40 or IL-12p35 showed highly increased susceptibility 
to M. tuberculosis infection97. In turn, exogenous administration of IL-12p70 
increased resistance of BALB/c mice to M. tuberculosis infection98. 
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IL-12p40 can be induced in response to M. tuberculosis in mononuclear cells 
by ligation of TLR2 and TLR9 in vitro while TLR9 is required for IL-12p40 
induction in vivo38. Early induction of IL-12p40 during M. tuberculosis infection is 
crucial to enable the migration of infected dendritic cells to the draining lymph nodes 
followed by the activation of naïve T cells99. Although IL-12p40 homodimers  IL-
12(p40)2  can restore the delayed hypersensitivity response in IL-12p35/IL-12p40-
deficient mice, optimal expression of IFN-γ by antigen-specific T cells can only be 
achieved in the presence of IL-12p7097,100. Moreover, IL-12p70 is needed to maintain 
Th1 effector functions during M. tuberculosis infection, since exogenous IL-12p70 
can reconstitute protection in p40-/- mice that is again lost after IL-12p70 
removal101,102. This observation could be confirmed in humans with IL-12Rβ1-
deficiency that fail to maintain a Th1 effector memory population showing that IL-12 
plays indispensable roles not only in initiation but also maintenance of protection 
against mycobacteria102.  
 
 
Figure 3: Th1 cells activate infected macrophages. 
IL-12 induces IFN-γ production in Th1 cells via STAT4 activation that in turn 
activates infected macrophages. These macrophages induce the transcription of    
IFN-γ-responsive genes as iNos. 
  
  11 
1.2.3 Interferon-γ 
Interferon-γ (IFN-γ) is critical during intracellular bacterial and protozoal 
infections as well as tumor growth control, but aberrant IFN-γ production can induce 
autoimmune diseases103-107. Responses to IFN-γ are mediated through its interaction 
with the IFN-γ receptor that initiates the activation of STAT1 (Fig. 3)108. 
The importance of IFN-γ for the defense against M. tuberculosis has been 
demonstrated in experimental studies using knockout mice and was confirmed in 
patients with defects in signaling or production of IFN-γ as both show dramatically 
increased susceptibility to mycobacterial infections50,109-112. As previously discussed, 
CD4+ T cells play an important role during M. tuberculosis infection and are 
considered to be the main source of IFN-γ, whereas IFN-γ secreted by natural killer 
(NK) cells appears to be redundant113,114. 
 Early appearance of antigen-specific IFN-γ-producing CD4+ T cells in the 
lungs coincided with earlier restriction of growth after aerosol M. tuberculosis 
infection115. Furthermore, a delay in priming of effector T cells led to increased 
bacterial burden in the lungs63.  
T cells elicit the bactericidal effects of infected macrophages. IFN-γ-activated 
macrophages were found to overcome bacteria-induced blockage of phagosome 
maturation and increased presentation of mycobacterial peptides to T cells and 
upregulated nitric oxide synthase 2 (iNOS2), an enzyme that produces nitric oxide 
(NO) and is involved in bacterial killing116,117. The role of NO in the control of 
mycobacterial intracellular growth is well established in the mouse model where  
Nos2-/- mice displayed increased susceptibility to M. tuberculosis infection. In 
humans, iNOS and NO production has been reported in alveolar macrophages in 
response to infection106,118-122. However, the role of NO in protection during human 
infection is controversial.  
In the addition to the effect of  IFN-γ on macrophages, it also was found in 
mouse radiation chimeras that responsiveness to IFN-γ by non-hematopoietic cells is 
involved in the protective immunity to M. tuberculosis55. 
Although the relevance of IFN-γ-producing T cells in protection is not up for 
debate, the numbers of IFN-γ-secreting T cells after vaccination do not always 
correlate with increased protection against M. tuberculosis infection123,124. This 
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suggests that more factors than IFN-γ production by CD4+ T cells should be assessed 
to determine protective immune responses to M. tuberculosis infection49. 
 
1.2.4 Interleukin-6 
IL-6 is involved in innate and adaptive immunity and is produced by 
mononuclear phagocytes, endothelial cells, fibroblasts, adipocytes and muscle cells73. 
It is induced in response to pathogens, TNF and IL-1. IL-6 signals are transmitted via 
a receptor complex consisting of IL-6Rα and gp130, the common IL-6 family co-
receptor. Binding of IL-6 to the receptor complex initiates activation of JAK1 
followed by recruitment of several signaling molecule such as STAT3 and SHP2. 
STAT3, once phosphorylated, dimerizes and acts as a transcription factor in the 
nucleus, and SHP2 links IL-6 to the Ras-MAP kinase pathway. Depending on the 
target cell, IL-6 stimulates secretion of acute phase proteins by hepatocytes, 
neutrophil production in the bone marrow, growth of B lymphocytes and generation 
of Th17 cells73.  
Historically, IL-6 has been regarded as a pro-inflammatory cytokine, but 
recently anti-inflammatory functions of IL-6 have also been described, which will be 
discussed in detail later125,126. 
M. tuberculosis-infected human and murine macrophages secrete IL-6 and 
elevated IL-6 serum levels are found in tuberculosis patients127-129. However, the role 
of IL-6 during infection with M. tuberculosis is not well understood.  
IL-6-deficient mice displayed increased susceptibility to M. tuberculosis 
infection compared to control mice, but only after a systemic high dose infection130. 
In the low-dose aerosol model, which mimics the natural route of infection, Il-6-/- 
mice only initially showed elevated bacterial levels131. In contrast, in vitro studies 
have shown that high levels of IL-6 impair T cell proliferation of antigen-specific T 
cells, reduce the responsiveness to IFN-γ of infected macrophages and counteract 
TNF-mediated mycobactericidal activities in macrophages132-134. 
 
 
1.2.5 Interleukin-17 
IL-17 can be produced by γδ T cells and Th17 cells and has been shown to be 
involved in the attraction of neutrophils to the site of infection135-138. The 
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development of Th17 cells depends on STAT3 activation (by IL-6, IL-21, IL-23) and 
TGF-β and is counter-regulated by Th1 cells139,140.   
 In mice, IL-17 is mainly secreted by γδ T cells during M. tuberculosis and 
early BCG infection141,142. Additionally, numbers of IL-17 producing γδ T cells were 
elevated in tuberculosis patients compared to healthy donors142,143. Although the lack 
of IL-17 or IL-17R does not impair the ability of mice to control a low dose aerosol 
M. tuberculosis infection, deficient mice were unable to control M. tuberculosis after 
a high dose intratracheal infection144,145. Thus, the relevance of IL-17 for the control 
of M. tuberculosis infection needs to be further investigated.  
However, the impact of IL-17 on granuloma formation and pathology have 
been suggested since BCG-infection of Il-17a-/- mice showed impaired granuloma 
maturation146,147. On the other hand, repeated BCG-immunizations of M. 
tuberculosis-infected mice led to increased infiltration of neutrophils and tissue 
damage in the lungs associated to elevated IL-17 levels146. 
Interestingly, high numbers of neutrophils have been associated with 
susceptibility to M. tuberculosis infection in mice 55,146-148. In Ifn-γ-/- mice infiltrating 
neutrophils could be related to high levels of IL-1755. Another hint for a detrimental 
effect of high IL-17 levels in M. tuberculosis  infection was found in IL-27R deficient 
mice. These mice showed lower bacterial burdens compared to control mice but 
developed enlarged granulomas and succumbed earlier to infection most likely due to 
enhanced IL-17 responses148.  
 
1.3 SOCS PROTEINS 
The family of suppressor of cytokine signaling (SOCS) proteins consists of 8 
members (cytokine inducible SH2 protein, CIS, SOCS1-7), and all are main regulators 
of intracellular signal transduction mediated through the JAK-STAT pathway. All 
SOCS proteins share a modular organization with a C-terminal SOCS box, a central 
SH2 domain and an amino-terminal domain of variable length (Fig. 4).  The SOCS-box 
was shown to interact with additional proteins to form an E3 ubiquitin ligase complex, 
initiating ubiquitination of target proteins, followed by proteosomal degradation of 
bound signaling complexes as JAKs and cytokine receptors149-151. The SH2 domain of 
SOCS proteins determines the specificity for their receptors152,153.  
Both deletion and overexpression of SOCS proteins in animal models provided 
insights into their importance in regulating the responsiveness to cytokines, growth 
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factors and hormones but also showed the specificity of SOCS proteins for certain 
receptors154. In particular, SOCS1 and SOCS3 were found to balance immune functions 
by influencing sensitivity to cytokines, modulating the differentiation of immune cell 
populations as well as their activation.  
 To date, SOCS1 and SOCS3 are the most studied members of the SOCS family. 
They both contain an additional N-terminal kinase inhibitory region (KIR) that is 
absent in other SOCS proteins. The KIR of SOCS1 and SOCS3 can directly inhibit 
JAK tyrosine kinase activity by acting as a pseudo-substrate, and thereby blocks the 
interaction of JAK with their substrate STAT molecules. Although SOCS1 preferably 
binds directly to the JAK activation loop, the SH2 domain of SOCS3 binds to the 
cytokine receptor.  Using this mechanism, JAK inhibition by SOCS1 and SOCS3 takes 
place even in the absence of the SOCS box155,156.  
 
 
 
 
 
 
 
Figure 4: SOCS proteins. A: Schematic structure of SOCS1 and SOCS3 proteins is 
shown. B: SOCS1 and SOCS3 binding to JAK or cytokine receptor.  
 
1.4 SOCS1 
SOCS1 expression can rapidly be induced by many cytokines, especially IFNs, 
and serves as a classical feedback loop inhibiting its inducing pathways157,158. 
Importantly, Socs1 mRNA expression increases even in response to microbial 
molecules such as LPS, Pam3Cys and CpG oligonucleotides that signal via TLR159-162.  
Furthermore, hormones like insulin163, cardiotrophin164 or glucocorticoids165 have been 
shown to stimulate SOCS1 expression.  
SOCS1 can bind to the catalytic domain of JAK2 and to TYK2, another 
molecule of the JAK family, which mediates IFN-α/β signaling. SOCS1 has also 
been shown to bind directly to type I IFN receptors (IFNar1)166 and to the IFN-γ 
receptor, efficiently inhibiting STAT1-mediated signaling154,166,167.  
A 
B 
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1.4.1 SOCS1-/- mice 
Mice deficient for SOCS1 die within 3 weeks after birth due to fatty 
degeneration and necrosis of the liver168,169. Additionally, these mice show retarded 
growth, lymphopenia and multi-organ haematopoetic infiltrates168,169. This 
inflammatory disease could be related to hyper-responsiveness of Socs1-/- mice to 
IFN-γ, because mice with an additional knockout of IFN-γ or STAT1 survive until 
adulthood170,171. Moreover, Socs1-/- mice that were treated with neutralizing IFN-γ 
antibodies from birth reached adulthood but died of myocarditis172. Indications for an 
involvement of T cells and NK T cells as a probable source of enhanced levels of 
IFN-γ  secretion were found in T and NK T cell-deficient Rag2-/-/Socs1-/- mice that are 
healthy to at least 3 month of age, and in the finding that Socs1-/- mice transgenic for 
SOCS1 in T cells survive171. However, conditional deletion of SOCS1 in T and NKT 
cells or in macrophages is not sufficient for the hyper-inflammation173.  Requirement 
of non-hematopoietic cells for detrimental inflammation could be excluded, as 
chimeric mice, which received Socs1-/- bone marrow after radiation, showed 
decreased survival174. Altogether, lethality caused by SOCS1-deficiency is mainly due 
to an exacerbated secretion of IFN-γ by T and NKT cells during the neonatal period 
and to an increased sensitivity of myeloid cells to IFN-γ.  
 In contrast, Socs1-/- mice crossed to IFNar1-/- mice survived beyond weaning, 
indicating that even type I IFN contributes to the lethal inflammation166. Besides the 
rescue of SOCS1-deficient mice by IFN depletion, Socs1-/- mouse strains crossed to 
Stat1-/-, Stat4-/- or Stat6-/- mice are partially protected from neonatal lethality, but 
nevertheless displayed chronic inflammation with aberrant T cell activation175-177. 
STAT6 and STAT4 are two STAT family members that specifically mediate signals 
that emanate from the IL-4/ IL-13 and IL-12 receptors, showing that SOCS1 also 
affects IL-4 and IL-12 signaling. Uncontrolled responses to IL-12, which is an 
important activator of IFN-γ secretion by T cells, could contribute to increased IFN-γ 
levels and therefore to the development of inflammation in Socs1-/- mice175.  
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1.4.2 SOCS1 in immunity  
Socs1-/- mice are hypersensitive to LPS-induced endotoxic shock, associated 
with increased levels of IL-12 and TNF178,179. Surprisingly, even though Ifn-γ-/- mice 
are highly resistant to endotoxic shock180, additional deletion of IFN-γ or STAT1 
does not rescue Socs1-/- mice from lethal LPS injection, demonstrating that SOCS1 
even attenuates IFN-γ-independent mechanisms178-180. Furthermore, elevated 
sensitivity to endotoxin shock was observed in Socs1fl/fl LysM-cre mice (see 
description of mouse strain in material and methods) lacking SOCS1 specifically in 
macrophages and neutrophils181.  
 Increased sensitivity to LPS suggests an interaction of SOCS1 with 
components of the TLR signaling. In fact, binding of SOCS1 to IRAK1 and the p65 
subunit of NF-κΒ has been shown to destabilize and limit NF-kB 
activation178,179,182,183. SOCS1 can also bind to the apoptosis-regulating kinase 1 and 
regulates mitogen-activated protein kinases JNK and p38184. Moreover, SOCS1 was 
shown to mediate the degradation of the adaptor protein MAL that is involved in 
TLR2 and TLR4 signaling185. However, results from other investigators could not 
confirm a direct effect of SOCS1 on TLR signaling186,187. SOCS1 overexpression did 
not affect TLR signaling; instead the inhibition of IFN-α/β-mediated STAT1 
activation by SOCS1 may account for the observed sensitivity to LPS in                  
Ifn-γ-/-/Socs1-/- mice186,187. Thus, further work is required to clarify whether SOCS1 is 
directly involved in the regulation of TLR signaling.  
 
1.4.3 SOCS1 in infectious diseases 
A wide range of pathogens including parasites, bacteria and viruses are potent 
stimulators of SOCS1 expression. Despite obvious differences in the type of 
protective or deleterious immune response elicited by different pathogens, for most 
intracellular infections studied, SOCS1 expression is associated to an increase in 
susceptibility to the infection by facilitating pathogen replication. However, SOCS1 
may on the other hand also reduce the pathological outcome of infections by 
hampering inflammatory reactions.  
Several viral infections including herpes simplex virus, human respiratory 
virus, HIV and hepatitis C virus were found to induce SOCS1 expression188-191. 
Importantly, silencing of SOCS1 increased type I IFN signaling and resulted in 
inhibited viral replication in a human respiratory virus model189. Accordingly, Socs1-
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deficient mice showed increased type I IFN-mediated resistance to Semliki Forest-
virus166,170. However, unrestrained immune responses cause damaging 
immunopathology in other virus infections. In these cases, impairment of cytokine 
responses with SOCS1 may prevent inflammatory damage. Thus, in a vaccinia virus 
infection model, mice could be protected against lethal virus infection by the 
administration of a peptide mimicking the SOCS1 KIR region192.  
In parasite infections, SOCS1 has been shown to inhibit responsiveness to 
IFN-γ, as in an in vitro model Socs1-/- macrophages were capable of killing 
Leishmania major at significantly decreased IFN-γ concentrations compared to 
SOCS1-sufficient macrophages170. However, increased pro-inflammatory signaling 
was not beneficial in vivo as Socs1+/- mice infected with L. major showed worsened 
pathology without a reduction in numbers of parasites193. 
 Studies on the role of SOCS1 in bacterial infections mainly focused on 
intracellular infections, in which IFN-γ plays a major protective role. Research from 
our laboratory demonstrated that Chlamydia pneumoniae infection of macrophages 
induced SOCS1 expression194. Infected Socs1-/- macrophages displayed lower 
bacterial titers and higher levels of IFN-regulated genes as iNos and indoleamine 
dioxygenase that participate in the control of intracellular bacteria. Rag1-/-/Socs1-/- 
mice showed 10-fold lower bacteria numbers in lungs than controls 6 days after 
infection. However,  Rag1-/-/Socs1-/- mice died within seven days after infection with 
C. pneumoniae showing a severe pulmonary inflammation, whereas Rag1-/- mice 
survived for more than 60 days. Thus, SOCS1 has a crucial role in preventing acute 
lethal inflammation in C. pneumoniae infection. 
 Infections with different mycobacterial species such as M. bovis195, M. 
avium196 and M. tuberculosis were found to induce SOCS1 expression in 
macrophages195-198. This SOCS1 induction was shown to be mediated by different 
innate immune receptors as TLR2 and DC-SIGN in mycobacterial-infected myeloid 
cells198. Knockdown of SOCS1 using siRNA in mouse DCs resulted in increased 
killing of virulent M. tuberculosis198. However, whether deletion of SOCS1 is 
beneficial for the outcome of mycobacterial infections in vivo remains to be 
investigated and will be discussed in this thesis. 
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1.5 SOCS2 
SOCS2 is induced in response to growth hormone (GH), prolactin, insulin, 
lipoxin, LPS and several cytokines199,200. Compared to SOCS1 and SOCS3, SOCS2 
shows a complete different spectrum of functions, with GH and insulin-like growth 
factor signaling as main targets of SOCS2 inhibition. Additionally, several reports 
indicate that SOCS2 not only regulates GH receptor signaling but may also be involved 
in responses to infection201,202. In contrast to SOCS1 and SOCS3, SOCS2 lacks the N-
terminal KIR domain so that the inhibitory function of SOCS2 is dependent on 
competitive binding via its SH2 domain and, even more importantly, on the 
ubiquitination and proteasomal degradation of the interacting receptor200. 
In contrast to Socs1-/- mice, Socs2-/- mice are viable. However, Socs2-/- mice show 
a 40% increase in body weight alike GH-transgenic mice, and overgrowth of Socs2-/- 
mice could be attenuated by an additional deletion of STAT5, the STAT molecule that 
mediates GH signal transduction 203,204.  
 
1.5.1 SOCS2 in immunity and infection 
Silencing of SOCS2 in human immature DCs demonstrated that the expression 
of SOCS2 was required for maturation of DCs after LPS stimulation199. Furthermore, 
Socs2-/- DCs were refractory to anti-inflammatory mediators like lipoxin (LXA4) and 
showed in turn increased expression of pro-inflammatory cytokines in response to 
microbial stimulation202. Socs2-/- mice infected with Toxoplasma gondii showed 
uncontrolled production of pro-inflammatory cytokines, aberrant leukocyte infiltration 
and elevated mortality that was most probably due to hyper-responsive DCs202. 
Regarding T cell responses, SOCS2-deficient CD4+ T cells displayed a Th2 
predisposition, and Socs2-/- mice showed enhanced Th2 responses to helminthic 
infections, atrophic dermatitis and allergic lung inflammation201. This suggested 
SOCS2 as an inhibitor of Th2 development.  
Even though SOCS2 is expressed in Th1 cells, Leishmania major-infected  
Socs2-/- mice showed the same level of disease progression than control mice, 
indicating that despite its potential involvement in Th1 immune responses, SOCS2 is 
not involved in the control of cutaneous leishmaniasis193. Yet, a role for SOCS2 in 
other Th1-controlled infections has not been studied and will be discussed later as part 
of this thesis. 
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1.6 SOCS3 AND GP130 
SOCS3 can be induced by different cytokines like leukemia inhibitory factor 
(LIF), IL-11, IL-10, IL-2, IL-6,158,205-208 hormones including ciliary neutrophilic factor, 
leptin, prolactin and growth hormones209-212 but also by microbial molecular patterns as 
LPS or CpG162,213. 
SOCS3 is an important endogenous regulator of STAT3-mediated signaling. 
Interestingly, not all cytokine signaling pathways that activate STAT3 are SOCS3-
regulated since SOCS3 binds to the gp130 and selected receptor subunits, whereas the 
signaling of IL-10 that also stimulates STAT3-activation is unaffected by SOCS3 
(Fig. 5)77,125,126,214,215. This is explained by the ability of SOCS3 to bind to the IL-6 
receptor subunit gp130 but not to the IL-10 receptor (Fig. 5)126,153,216. Furthermore, 
SOCS3 inhibits non-gp130-mediated cytokine and hormone receptor signaling 
pathways activated by G-CSF, leptin, IL-12 and IFN206,215,217-220.   
The glycoprotein gp130 is a promiscuous cytokine receptor subunit that 
mediates signaling by IL-6 and all other cytokines belonging to the IL-6 family such 
as IL-11, IL-27, oncostatin M, cardiotropin 1, cardiotropin-like cytokine and LIF221. 
IL-6 binds to the IL-6R alpha chain, recruits gp130 and forms a hexameric complex 
consisting of two IL-6 bound to two IL-6Rα and gp130 subunits222,223. It was found 
that gp130 could be present on hematopoetic cells depending on their activation 
status but also on non-hematopoetic cells224-226.  
Binding of the ligand to gp130 induces activation of JAK1 kinases, which 
results in tyrosine phosphorylation of gp130. This creates binding sites for signaling 
transmitting factors at two different sites: phosphorylation of the four membrane-
distal tyrosines leads to binding of STAT1 and STAT3, whereas phosphorylation of 
the membrane-proximal tyrosine (Y757) enables binding of the Src-homology 
tyrosine phosphatase-2 (SHP2)227-230. These bound molecules are in turn activated 
and trigger distinct intracellular signaling cascades. 
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Figure 5: SOCS3-mediated inhibition of gp130 and non-gp130 signals but not of 
IL-10-signaling.  
Since SOCS3 cannot bind to the IL-10 receptor, STAT3 activation in response to IL-
10 is unimpaired in the presence of SOCS3, whereas gp130, GSCF and leptin 
receptor signals are inhibited by SOCS3. 
 
 
 Interestingly, Y757 (SHP2-binding site) is also the binding site for SOCS3 and 
required for SOCS3-mediated inhibition of STAT3 activation231. Therefore, a 
mutation at Y757 has two effects: abrogation of SHP2 signaling and deletion of 
SOCS3-mediated STAT3 inhibition.  
 
  
gp130 e. g. GCSF, leptin receptor  
IL-10 receptor 
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1.6.1 SOCS3 and gp130 mutations in mice 
SOCS3 knockout mice die during embryogenesis due to placental 
defects232,233. Mortality is caused by enhanced LIF signaling in the absence of SOCS3 
causing an altered trophoblast differentiation234. However, mice with a conditional 
knockdown for SOCS3 in specific tissues or cell linages survive and have been used 
for targeted SOCS3 studies (see in materials and methods). 
Since the knockdown of gp130 leads to embryonic or perinatal lethality, mice 
with conditional knockdowns for gp130 or mutations ablating either the STAT1/3 
binding or SHP2/SOCS3 binding are used to dissect the role of gp130 in mouse 
models235. To study the role of SOCS3 within gp130 signaling, two different models 
can be used: One model, gp130F759 mice, the mouse gp130 is replaced with human 
gp130 mutant cDNA, in which the crucial tyrosine for SOCS3 binding in position 
759 (corresponds to 757 in the mouse) is replaced by phenylalanine (gp130F759 mice), 
and the other model, in which tyrosine 757 is directly substituted by phenylalanine 
(gp130F/F mice)236,237. These models show similarities, a prolonged activation of 
STAT3 in response to gp130-activating factors was found in both models confirming 
the impairment of SOCS3 function by these mutations236,238. Phenotypically these 
mice developed splenomegaly that could be accounted to increased STAT3 activation 
by IL-6 as it is also found in IL-6/IL-6Rα transgenic mice236,237,239. Furthermore, 
gp130F759 mice showed autoimmune arthritis and lymphadenopathy, whereas in 
gp130F/F mice gastric adenoma formation and a reduced life span was found225,226,240.  
Combination of gp130F/F mice with deletion of IL-6 (gp130F/F/Il-6-/-) or reduction of 
STAT3 levels (gp130F/F/Stat3+/-), allows to study the underlying mechanisms caused 
by the changed gp130 signaling238.  
 
  
  22 
1.6.2 SOCS3 in myeloid cells 
Mice with a conditional knockdown of SOCS3 in myeloid cells highlighted 
the crucial role of SOCS3 in suppression and termination of IL-6/gp130-mediated 
signaling. SOCS3-deficient macrophages stimulated with IL-6 displayed an increased 
magnitude and duration of STAT1 and STAT3 activation in comparison to 
controls125,126,241. This prolonged STAT3 activation is a hallmark of anti-
inflammatory IL-10 signaling and LPS-induced pro-inflammatory responses like 
secretion of TNF and IL-12 were reduced in the presence of IL-6 in SOCS3-deficient 
macrophages (Fig. 6). The importance of SOCS3-regulated STAT3 activation was 
confirmed in gp130F/F macrophages that responded to IL-6 similar as to IL-10 under 
LPS stimulation242. Additionally, Croker (2003), Lang (2003) and co-workers found 
an increased STAT1 activation and elevated levels of IFN-γ responsive genes in 
response to IL-6 using SOCS3-deficient macrophages (Fig. 6)125,241.  
The anti-inflammatory properties of IL-6 in the absence of SOCS3 or SOCS3-
binding may explain why mice deficient for SOCS3 in myeloid cells are resistant to 
LPS-induced endotoxic shock whereas Stat3-/- mice are highly susceptible126,243. 
Moreover, SOCS3-deficient DCs were found to be capable of suppressing the 
development of experimental autoimmune encephalitis (EAE)244,245.  
Furthermore, deletion of SOCS3 in the myeloid or hematopoetic cells 
increased the numbers of neutrophils, which showed increased survival and 
proliferative capacity214,247. Following GCSF injection in vivo, SOCS3-deficient mice 
developed neutrophilia, and a spectrum of inflammatory pathologies characterized by 
neutrophil infiltration in multiples tissues248.  
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Figure 6: SOCS3 inhibits anti-inflammatory and IFN-inducible genes in 
response to LPS in presence of IL-6 (adapted from 246).  
LPS-induced SOCS3 modulates IL-6 signaling leading to pro-inflammatory 
responses (A). In contrast in the absence of SOCS3, anti-inflammatory responses and 
expression of IFN-γ-inducible genes are observed (B). 
 
  
1.6.3 SOCS3 in T cells 
Even though T cell development in the thymus is unaffected by SOCS3249, 
several models suggest a role for SOCS3 in T cell proliferation. One indication for its 
regulatory role is the fact that SOCS3 levels are high in resting T cells, whereas they 
are low in activated T cells250.  Furthermore, T cells overexpressing SOCS3 showed a 
reduced proliferation upon T cell receptor stimulation251,252, whereas SOCS3-
deficient T cells were hyper-proliferative towards T cell receptor stimulation253,254. 
Interestingly, T cells from gp130F/F mice behaved alike SOCS3-deficient T cells, 
A 
B 
  24 
suggesting that hypersensitivity to gp130 cytokines may drive this enhanced 
proliferation253.  
 SOCS3 protein levels may influence the Th1/Th2 balance, as expression was 
found to be low in Th1 cells and high in Th2 cells255,256. Accordingly, overexpression 
of SOCS3 in mice resulted in elevated Th2 responses and hypersensitivity to allergic 
diseases256. A possible explanation for the increased Th2 development under high 
SOCS3 levels might be that binding of SOCS3 to IL-12Rβ2 inhibits IL-12-mediated 
STAT4 activation that in turn impairs Th1 differentiation256,257.  
Interestingly, a conditional knockdown for SOCS3 in T cells mice showed 
reduced Th2 responses together with increased numbers of Th3-like T cells secreting 
IL-10 and TGF-β258. Unexpectedly, Th1 responses were not elevated in the absence 
of SOCS3, which may have been caused by the presence of immunosuppressive 
cytokines258.  
Other reports indicated only minimal effects of SOCS3 deletion in T cells on 
the Th1/Th2 balance but found an increased Th17 generation and enhanced STAT3 
activation in response to IL-23249. This data was confirmed in a study of an 
atherosclerosis model using mice with a T cell specific SOCS3 knockdown as well as 
in a rheumatoid arthritis model, in which mice lacking SOCS3 in hematopoietic and 
endothelial cells showed increased Th17 development259,260. These findings fit well 
with the known mechanism for Th17 differentiation, as STAT3 activation either by 
IL-23 or IL-6 is crucial for Th17 development (Fig. 7). Furthermore, TGF-β, another 
cytokine necessary for Th17 generation, was shown to inhibit SOCS3 expression with 
the resulting prolonged STAT3 activation and thereby promoting Th17 
development261.  
 
 
Figure 7:  Role of SOCS3 in Th17 cell development. 
STAT3 activation is essential for the generation of Th17 cells and can be inhibited by 
SOCS3. 
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No SOCS3 protein expression was found in Tregs262. Accordingly, in SOCS3-
deficient T cells no defects in Treg differentiation and function were reported254. 
Recently, SOCS3 has been assigned a role in development of memory CD8+ T cells 
since numbers of memory CD8+ T cells were dramatically reduced in the absence of 
SOCS3 in T cells263,264.   
 
1.6.4 SOCS3 in infectious diseases  
Similar to SOCS1 and SOCS2, SOCS3 expression can be stimulated by both 
cytokines and TLR agonists.  Additionally, several pathogens including viruses, 
bacteria and parasites have been shown to induce SOCS3 expression. Due to the 
diversity of described SOCS3 actions, it is hard to predict in which cases SOCS3 
expression will be beneficial for the host.  
 SOCS3 was found to inhibit STAT1 activation in response to type I IFNs but 
was less effective than SOCS1 in such function215,219. Infections with several viruses 
stimulated SOCS3 expression that correlated with reduced STAT1 activation in 
response to type I IFNs. Silencing of SOCS3 significantly increased IFN signaling 
and hampered viral replication. Similar findings were obtained during different viral 
infections e.g. HSV, Influenza A, hepatitis C virus and Epstein Barr virus infection 
indicating that increased SOCS3 expression improves viral replication265-269. 
 Surprisingly, mice with a T cell-specific SOCS3 deletion showed increased T 
cell activation and viral clearance without development of immunopathology during 
the infection with lymphocytic chriomeningitis virus (LCMV)270. Treatment of 
LCMV-infected mice with IL-7 repressed SOCS3 expression and promoted IL-6 
production, which resulted in enhanced T cell effector functions and viral clearance. 
On the contrary, Leishmania major-infected mice were more susceptible in the 
absence of SOCS3 in T cells. In this case, SOCS3 deficiency in T cells led to 
increased anti-inflammatory TGF-β secretion promoting the infection258.   
 Infection of macrophages with M. avium and M. bovis raised SOCS1 and 
SOCS3 levels in a TLR2-NOTCH1 dependent pathway195,196,271. In clinical studies, 
patients with active tuberculosis were found to have higher SOCS3 expression levels 
in whole blood and T cells in comparison to latently infected controls272,273. 
Accordingly, SOCS3 expression decreased under chemotherapy treatment indicating 
that SOCS3 expression could be interpreted as an on-going infection response272,273. 
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However, to prove that SOCS3 plays a crucial role for tuberculosis control, more 
work needs to be done. This was one of the objectives of my thesis. 
  Regarding SOCS3-ablations due to gp130 mutations, gp130F759 mice showed 
an attenuated early phase of defense against Listeria monocytogenes infection 
resulting in higher bacterial loads and mortality most probably due to insufficient 
elevation of IFN-γ levels274. Furthermore, low IFN-γ titers led to increased 
susceptibility to Toxoplasma gondii in mice deficient for SOCS3 in myeloid cells as 
well as in gp130F/F mice.275,276 In both mouse strains, lower IL-12p40 and therefore 
lower IFN-γ levels after infection compared to control mice were found. Interestingly, 
addition of IL-12 as well as neutralization of IL-6 could restore the wild type (WT) 
phenotype in both models demonstrating that an altered IL-6 signaling was 
responsible for the observed increased susceptibility275,276. 
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2 AIMS 
M. tuberculosis is a highly successful pathogen. Even though the literature is extensive, 
detailed reasons why a latent tuberculosis patient will convert to active disease and the 
mechanisms that regulate the control of M. tuberculosis are not completely understood. 
More knowledge about protective immune responses during M. tuberculosis infection 
is required for the design of prophylaxis and therapy.  
SOCS proteins are non-redundant regulators of immune responses through 
inhibition of cytokine signaling. Therefore, these molecules are interesting target 
candidates that may modulate the outcome of infections.  
In my thesis work, I have studied the role of SOCS1, SOCS2 and SOCS3, 
which have different specific cytokine signaling pathways as their targets, in the 
outcome of mycobacterial infections. 
 
Specific questions: 
 
SOCS1 
• How is SOCS1 expression regulated in mycobacteria-infected macrophages? 
• What is the role of SOCS1 in the regulation of intracellular bacterial levels and 
cytokine expression in mycobacteria-infected macrophages in vitro?  
• What is the role of SOCS1 in vivo during M. tuberculosis or BCG infection 
regarding  
o Bacterial loads 
o Cytokine responses 
o Immunopathology? 
 
SOCS2 
• How is SOCS2 expression regulated in response to TLR stimulation? 
• How is SOCS2 expression regulated in mycobacteria-infected macrophages? 
• Is there a role for SOCS2 during M. tuberculosis infection in vivo? 
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SOCS3 
• How is SOCS3 expression regulated in mycobacteria-infected macrophages? 
• Which function has SOCS3 in macrophages/DCs during mycobacterial 
infections regarding the regulation of  
o Bacterial loads 
o Cytokine responses 
o Immunopathology? 
• What is the role of SOCS3 in T cells during M. tuberculosis infection in vivo 
regarding the regulation of 
o Bacterial loads 
o Cytokine responses 
o Immunopathology? 
• Which function has gp130 signaling in SOCS3-deficient models in vivo and in 
vitro during mycobacterial infections? 
 
 
  
 
  29 
3 MATERIAL AND METHODS 
The methods applied in our studies are described in detail in the published articles and 
in the manuscript. Here, I want to give an overview about the genetically modified mice 
that have been used. 
 
SOCS-unrelated 
mouse strain type of modification effect 
Rag1-/- knockout disruption of the Rag1 gene in all cells 
no mature B and T cells  
MyD88-/- knockout disruption of the MyD88 gene in all cells  
Irf3-/- knockout disruption of the Irf3 gene in all cells 
Ifn-γ-/- knockout disruption of the Ifn-γ gene in all cells 
 
SOCS proteins and SOCS-related 
mouse strain type of modification effect 
Rag1-/-/Socs1-/- double knockout no mature B and T cells   
disruption of the Rag1 and Socs1 gene in 
all cells 
Ifn-γ-/-/ Socs1-/- double knockout disruption of  the Ifn-γ and Socs1 gene in 
all cells 
Socs1fl/fl LysM cre* conditional 
knockdown 
excision of the Socs1 gene in myeloid 
cells 
Socs2-/- knockout disruption of the Socs2 gene in all cells 
Socs3fl/fl LysM cre* conditional 
knockdown 
excision of the Socs3 gene in myeloid 
cells 
Socs3fl/fl lck cre* conditional 
knockdown 
excision of the Socs3 gene in T cells 
gp130F/F knockin mutation of the SOCS3 binding site in 
gp130 in all cells 
gp130F/F/Il-6-/- knockin/knockout mutation of the SOCS3 binding site in 
gp130 in all cells  
disruption of the Il-6 gene in all cells 
gp130F/F/Stat3+/- knockin/knockout mutation of the SOCS3 binding site in 
gp130 in all cells  
heterozygous for Stat3 gene knockout 
 
*Conditional knockdown: 
Mice were generated using the Cre-lox combination system, in which the Cre DNA-
recombinase is expressed under a cell-specific promoter. Although the target gene is 
flanked by LoxP sequences in all cells for recognition by the Cre enzyme, it will only 
be deleted specifically in Cre-expressing cells. The corresponding WT mice contain the 
floxed gene (Socs1fl/fl and Socs3fl/fl) but are negative for Cre expression. 
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4 RESULTS AND DISCUSSION 
4.1 SOCS1 DURING M. TUBERCULOSIS INFECTION (PAPER I) 
 
IFN-γ is essential for protection against M. tuberculosis infection. SOCS1 is 
induced during infection of macrophages with Mycobacterium avium and 
Mycobacterium bovis BCG, and may thereby inhibit responses to IFN-γ and play a 
central role in the outcome of mycobacterial infections195,196. Thus, we hypothesized 
that stimulation of SOCS1 expression could constitute an immune-escape mechanism 
for the establishment and chronicity of M. tuberculosis infection. 
 
How is SOCS1 expression regulated in mycobacteria-infected macrophages? 
We found that Socs1 mRNA was stimulated during BCG and M. tuberculosis 
infections in vitro in human and murine macrophages as well as in a mouse model in 
lung tissue during infections. Using macrophages from genetically manipulated mice, 
we found that the expression of Socs1 mRNA during BCG infection required 
phagocytosis and the presence of NOD2 and IFN-α/β receptors, the adaptor protein 
MyD88 and the common transcription factor NF-κΒ. This shows that TLR and non-
TLR signals cooperate in optimal Socs1 mRNA expression in mycobacteria-infected 
macrophages. Furthermore, our data was confirmed by a recent publication, in which 
M. tuberculosis-induced Socs1 mRNA expression was dependent on TLR and DC-
SIGN receptor 1 in human DCs198. Moreover, our finding of SOCS1 induction in lungs 
tissue of BCG and M. tuberculosis-infected mice is further supported by clinical data 
that demonstrated increased SOCS1 expression in induced sputum of tuberculosis 
patients compared to healthy individuals and patients with other lung diseases277.  
Mechanisms of SOCS1 action in the mouse model may therefore provide insights into 
the role of the molecule in determining the onset and course of active tuberculosis in 
patients. 
 
What is the role of SOCS1 in the regulation of intracellular bacterial levels and 
cytokine expression in mycobacteria-infected macrophages in vitro?  
To study the function of SOCS1 in vitro, we took advantage of cells derived 
from Socs1 knockout and conditional knockdown mice as well as SOCS1 mimetic 
peptides. We found that SOCS1 inhibited growth control of M. tuberculosis and BCG 
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in macrophages. Infected Socs1-/- macrophages showed lower mycobacterial numbers 
and expressed higher levels of IFN-γ-responsive genes, but interestingly, also higher 
levels of IFN-γ itself than infected control cells. In agreement, Socs1-/- macrophages 
secreted higher amounts of IFN-γ in response to IL-12 that was associated with 
increased IL-12Rβ1 but not IL-12 expression in infected Socs1-/- macrophages. 
Neutralization of IL-12 reduced the elevated IFN-γ expression in infected Socs1-/-- 
macrophages. Of importance, the improved control of M. tuberculosis and BCG by 
Socs1-/- macrophages was lost in Ifn-γ-/-/Socs1-/- macrophages, demonstrating that 
IFN-γ secretion mediated the improved mycobacterial control of Socs1-/- 
macrophages. Moreover, M. tuberculosis-infected WT macrophages were unimpaired 
in their response to addition of exogenous IFN-γ despite SOCS1 expression. 
Altogether, our results suggest that SOCS1 regulates the secretion rather than the 
response to IFN-γ, via controlling responses to IL-12 causing the increased 
mycobacterial resistance of Socs1-/- macrophages (Fig. 8). This mechanism is 
unexpected, as to our knowledge, all described effects of SOCS1 on infected host 
cells were explained by the inhibition of STAT1 signaling leading to impaired type I 
IFN-signaling for viral infections or IFN-γ-signaling for intracellular bacteria and  
parasites 166,170,189,195,196.  Since SOCS1 binds to JAK2 that is also associated with the 
IL-12 receptor, this interaction probably influences IL-12 signaling. Furthermore, 
Socs1-/-/Stat4-/- mice, deficient for the IL-12 signal-transmitting molecule STAT4, 
live longer than Socs1-/- mice175. This suggests an inhibitory role of SOCS1 on 
STAT4 activation and increased responses to IL-12 in absence of SOCS1 have been 
found in T cells and DCs175,278. Thus, our findings broaden the inhibitory spectrum of 
SOCS1 from IFN responses in macrophages to IL-12 responses during infections 
(Fig. 8). 
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Figure 8: M. tuberculosis-infected macrophages in presence (A) and absence (B) 
of SOCS1. 
Infection of macrophages with M. tuberculosis stimulates innate immune responses 
(1) such as the production of IL-12. Responses to IL-12 are inhibited in the presence 
of SOCS1 (2) leading to reduced IFN-γ induction and IFN-γ−signaling (3). Therefore, 
presence of SOCS1 results in higher bacterial numbers (4) and reduced                 
IFN-γ−induced effector mechanisms. 
 
 
To obtain a detailed overview about SOCS1-affected genes during M. 
tuberculosis infection in macrophages, we performed a genome wide expression 
microarray. In agreement with previous results, a significant fraction of the 
macrophage genome was altered after M. tuberculosis infection116,279. Unexpectedly, 
A 
B 
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the majority of infection-regulated genes was even stronger regulated in the absence 
of SOCS1, suggesting a major role of SOCS1 in the control of macrophage activity 
during M. tuberculosis infection. The majority of genes involved in the defense and 
immune responses and almost all IFN-γ−regulated genes showed higher levels in 
infected Socs1-/- macrophages, whereas genes that were decreased in infected control 
cells were even further downregulated in infected Socs1-/- macrophages. Altogether, 
our data implicates that the presence of SOCS1 attenuates both the negative and 
positive regulation of the majority of genes that change their expression after 
infection.  
 
What is the role of SOCS1 during in vivo M. tuberculosis or BCG infection regarding 
bacterial loads, cytokine responses and immunopathology? 
Importantly, the improved bacterial control in Socs1-/- macrophages in vitro 
was reflected in the role of SOCS1 during M. tuberculosis infection in vivo. Aerosol 
infection with M. tuberculosis of Rag1-/-/Socs1-/- as well as Socs1fl/fl LysM cre mice 
showed lower bacterial loads in the lungs 7 days after infection compared to control 
mice (Fig. 9). Moreover, Ifn-γ and iNos mRNA levels in the lungs of Rag1-/-/Socs1-/- 
and Socs1fl/fl LysM cre mice were elevated compared to control mice (Fig. 9). At this 
early stage of infection, mainly innate immune mechanisms are present, and no 
increase of IFN-γ in lungs of infected control mice was detected. Consistent with our 
in vitro results, lungs from infected Rag1-/-/Socs1-/- and Socs1fl/fl LysM cre mice 
showed higher levels of IFN-γ that are sufficient to impair bacterial growth in vivo, 
since no improved bacterial control was observed in Ifn-γ-/-/Socs1-/- mice compared to 
Ifn-γ-/- mice. 
 
Figure 9: SOCS1 in myeloid cells 7 days after M. tuberculosis infection.  
7 days after M. tuberculosis infection, bacterial loads in the lungs of individual 
Socs1fl/fl and Socs1fl/fl LysM cre mice and median were determined (A). Expression of 
Ifn-γ mRNA in lungs is shown in (B) as mean ±	 SEM. 
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Three weeks after infection, in conjunction with the appearance of IFN-γ 
producing T cells in lungs of aerosol infected mice, similar bacterial counts were 
registered in the lungs of Rag1-/-/Socs1-/-, Socs1fl/fl LysM-cre and their respective 
control mice. We suggest that, at this later time point, the advantage of the SOCS-
deficient host is lost when IFN-γ secretion by T cells is prominent and macrophages 
even in the presence of SOCS1 are able to respond to IFN-γ. Relevant to our 
observation, SOCS1 expression is elevated in the blood of patients with pulmonary 
tuberculosis that at the same time express an IFN-induced gene signature280. As we 
found no differences in IFN-γ and IFN-γ-regulated genes in control and Rag1-/-/Socs1-
/- mice at these later stage, it is possible that the inhibitory effects of SOCS1 can be 
shadowed by a potent Th1-mediated immunity.  
Additionally, both Rag1-/-/Socs1-/- and also Ifn-γ-/-/Socs1-/- mice showed a very 
severe pulmonary inflammation 3 weeks after M. tuberculosis infection. This 
inflammatory response was mediated by SOCS1 deficiency in non-macrophage cells, 
because it was not observed in M. tuberculosis-infected Socsfl/fl LysM-cre mice, 
which are lacking SOCS1 only in myeloid cells. We conclude that SOCS1-expressing 
non-macrophage cells are responsible for preventing a detrimental inflammation that 
is elicited at least partially in an IFN-γ-independent manner. This is an interesting 
finding as in the absence of SOCS1 inflammation was reported to be mediated to a 
great extent by increased IFN-γ secretion by T cells and elevated responsiveness of 
macrophages to IFN-γ170,171,173. SOCS1 has also been shown to play a role in type I 
IFN, IL-4, IL-13 and IL-12 signaling, but apart from IL-12, these cytokines are not 
classically associated to resistance against M. tuberculosis infections281,282. However, 
whether these cytokines can contribute to mycobacterial infection-mediated 
inflammation remains to be examined.  
Overall, we demonstrated that M. tuberculosis-induced SOCS1 by diminishing 
IL-12 responses impaired IFN-γ secretion by macrophages. This resulted in lower 
levels of IFN-γ-regulated genes and promoted M. tuberculosis infection leading to 
increased pulmonary bacterial levels in the lungs at early time points. Later during 
infection, mainly T cells produced IFN-γ and SOCS1 in non-macrophages cells 
protected mice from severe inflammation thereby allowing the establishment of 
chronic infection (Fig.10).  
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Figure 10: Role of SOCS1 at different stages of M. tuberculosis infection. 
SOCS1 in macrophages increases bacterial numbers at the early stage of infection, 
whereas it has no effect on bacterial control at later time points. SOCS1 in non-
macrophage cells (e. g. epithelial cells) hampers inflammation at later stages. 
 
 
4.2 SOCS2 (PAPER II) 
Little is known about the regulation of SOCS2 expression in immune cells. In 
paper II we investigated the regulation of SOCS2 expression in response to TLR4 
agonists and to Mycobacterium bovis BCG in macrophages.  
 
How is SOCS2 expression regulated in response to TLR4 stimulation? 
We demonstrated that LPS-induced SOCS2 expression in human monocyte-
derived DCs was dependent on the transcription factors IRF1 and IRF3 as shown by 
silencing IRFs. The expression and activation of IRF1 and IRF3 is known to be 
stimulated by type I IFNs, and neutralization of type I IFNs abolished Socs2 mRNA 
expression after TLR4 stimulation. Silencing of different STAT transcription factors 
revealed the requirement of STAT3 and STAT5 in LPS-induced Socs2 mRNA 
expression. TLR-signaling has been reported to mediate a direct induction of SOCS2 
expression283 but we clearly could show that inhibition of IRF1, IRF3 and IFN-α/β 
receptors severely impaired LPS-stimulated SOCS2 induction. 
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How is SOCS2 expression regulated in mycobacteria-infected macrophages? 
Socs2 mRNA levels increased in BMM after infection with M. bovis BCG. The 
reduction of Socs2 transcript induction in macrophages derived from Irf3-/- and  
MyD88-/- mice suggested the involvement of signaling via TLR or other innate immune 
receptors. 
 
Is there a role for SOCS2 during M. tuberculosis infection in vivo? 
Since Socs2 mRNA expression was stimulated by M. bovis BCG, we studied 
whether SOCS2 played a role in the outcome of infection with M. tuberculosis. Socs2-/- 
and control mice were infected via aerosol with M. tuberculosis and bacterial burdens 
in lungs and spleens were determined 6 weeks after infection (Fig. 11).  
 
Fig. 11: SOCS2 expression does not change M. tuberculosis infection. 
WT and Socs2-/- mice were infected via aerosol with M. tuberculosis Harlingen. Mice 
were sacrificed 6 weeks after infection and bacterial colony forming units (CFU) in 
lungs and spleens determined. Individual counts and median of each group is shown. 
 
  No differences in bacterial titers were detected, indicating that SOCS2 is mot 
involved in the control of M. tuberculosis. This result contrasts with the role of SOCS2 
during infection with Toxoplasma gondii that showed increased cumulative mortality in 
Socs2-/- mice202. The heightened morbidity and mortality of T. gondii-infected Socs2-/- 
mice was explained by the finding that Socs2-/- DCs were refractory to the anti-
inflammatory properties of the lipoxin LXA4202. Both M. tuberculosis and T. gondii 
induce LXA4, an eicosanoid mediator with potent anti-inflammatory properties, that 
e.g. reduces IL-12 secretion by DC284,285. However, only T. gondii-infected 5-
lipoygenase-deficient mice (that are deficient for LXA4) succumbed earlier to infection 
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than control mice due to lethal encephalitis, whereas M. tuberculosis-infected 5-
lipoxygenase-deficient mice displayed an improved control of infection without 
concominant immunopathology285,286. This indicates a vital role for LXA4 and its 
regulation by SOCS2 during T. gondii infection in prevention of fatal immune 
activation. However, our results suggest that SOCS2-mediated lipoxin LXA4 
regulation is redundant for the control of infection with M. tuberculosis. 
Regarding a possible role for SOCS2 in controlling T cells responses, enhanced 
generation of Th2 cells was described in helminth-infected Socs2-/- mice201. For M. 
tuberculosis control, specific Th1 cell-mediated immunity is fundamental 6 weeks after 
infection. Thus, we conclude that the absence of SOCS2 does not hamper Th1 
responses during M. tuberculosis infection, confirming previous findings, in which 
SOCS2 was redundant for the control of Leishmania major infection 193. 
These results suggest that although SOCS2 is induced during mycobacterial 
infections, its role is minor or redundant for disease control. 
 
4.3 SOCS3 DURING M. TUBERCULOSIS INFECTION (PAPER III) 
SOCS3 was shown to be induced in macrophages in response to mycobacterial 
infection with M. avium and M. bovis and in T cells of patients with active 
tuberculosis195,196,272. Since SOCS3 has multiple functions in the regulation of different 
cytokine signaling pathways with some of them unapparent in their function of 
tuberculosis control, we investigated the role of SOCS3 in the regulation of M. 
tuberculosis infection.  
 
How is SOCS3 expression regulated in mycobacteria-infected macrophages? 
 In a first set of experiments, we found that Socs3 mRNA expression was 
increased in lung tissue of M. tuberculosis and BCG-infected mice with around 10-fold 
higher levels during M. tuberculosis than in BCG infection. Socs3 transcript induction 
in infected BMM was dependent on MyD88 and NF-κΒ but not on IRF3. To study 
whether this SOCS3 induction is important during M. tuberculosis infection, we 
examined the outcome of infection in different mouse models. 
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Which function has SOCS3 in macrophages/DCs during mycobacterial infections 
regarding the regulation of bacterial loads, cytokine responses and immunopathology? 
 Mice deficient for SOCS3 in myeloid cells (Socs3fl/fl LysM cre mice) showed 
increased bacterial burdens in lungs and spleens from 16 days after infection with M. 
tuberculosis. Socs3fl/fl LysM cre mice also displayed enhanced immunopathology and 
succumbed 82 days after infection (median survival), whereas control mice survived 
for 150 days until the experiment was terminated. Moreover, increased bacterial loads 
in lungs and spleen were observed after BCG infection of Socs3fl/fl LysM cre mice, 
although differences to bacterial loads in control mice were smaller compared to those 
registered during M. tuberculosis infection.  
Next, we studied whether SOCS3-deficient macrophages were hampered in 
their control of mycobacterial growth. Surprisingly, Socs3fl/fl LysM cre BMM displayed 
unimpaired control of intracellular of M. tuberculosis replication and reduced bacterial 
loads in response to exogenous IFN-γ. Thus, defects of the bactericidal/ bacteriostatic 
capacity of  SOCS3-deficient macrophages are unlikely to cause the  increased in vivo 
susceptibility to M. tuberculosis of Socs3fl/fl LysM cre mice. In line with our data, 
previous work revealed that SOCS3-deficient macrophages could control T. gondii 
infection even though Socs3fl/fl LysM cre mice were highly susceptible to the infection 
with the parasite276. 
Thereafter, we analyzed the presence of cytokines and inflammatory mediators 
in supernatants of mycobacteria-infected macrophages. We found lower levels of TNF 
and IL-12p40 and higher levels of nitric oxide (NO) in supernatants of  SOCS3-
deficient macrophages after infection with M. tuberculosis or BCG and after 
stimulation with TLR-agonists in comparison to control cells. All three molecules –
TNF, IL-12 and NO- have been demonstrated to be critical for control of clinical and 
experimental mycobacterial infections82,83,96,116,117. The elevated NO levels could 
explain the slightly improved bacterial growth control in vitro, whereas reduced IL-
12p40 levels mainly would be important in vivo due to its crucial role in the generation 
of Th1 responses97,99,101. Previous studies showed reduced secretion of TNF and         
IL-12p40 in Socs3fl/fl LysM cre BMM in response to LPS, but only in co-culture with 
IL-6126. Interestingly, differences in TNF and IL-12p40 levels between mycobacteria-
infected Socs3fl/fl LysM cre and control BMM were found even in absence of 
exogenously added IL-6. Addition of recombinant IL-6 to the cultures further 
diminished IL-12 and TNF concentrations in supernatants of mycobacteria-infected 
Socs3fl/fl LysM cre BMM. Furthermore, it has previously been shown that neutralization 
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of IL-6 in IFN-γ/LPS stimulated cultures of Socs3fl/fl LysM cre BMM enhanced IL-
12p40 production276. The increased NO and iNOS levels in BCG-infected Socs3fl/fl 
LysM cre BMM could reflect the described IFN-γ-like response to IL-6 in Socs3fl/fl 
LysM cre BMM125,241.  
 Moreover, we found lower IL-12p40 expression levels in M. tuberculosis and 
BCG-infected SOCS3-deficient BMDC. Thus, we studied whether IFN-γ levels and 
secretion were impaired in lungs of M. tuberculosis-infected Socs3fl/fl LysM cre mice. 
Sixteen days after infection, lungs from Socs3fl/fl LysM cre mice contained significantly 
lower levels of Ifn-γ mRNA compared to control mice. At this time point, Ifn-γ mRNA  
accumulation in lungs from M. tuberculosis-infected control mice was mediated by T 
cells because depletion of CD4+ cells in control mice reduced IFN-γ levels down to 
levels found in Socs3fl/fl LysM cre mice. Moreover, the differences in susceptibility to 
infection of SOCS3fl/fl LysM cre and control mice were abrogated under CD4+ cell 
depletion.  
Surprisingly, Ifn-γ mRNA levels were only transiently reduced in Socs3fl/fl LysM 
cre mice, and no differences were detected 4 weeks after infection, although differences 
in bacterial levels at this time point were remarkable.  However, a delayed recruitment 
of antigen-specific T cells to the lungs was shown to underlie increased bacterial 
burdens in susceptible mouse strains25. These results suggest that a delay of T cell-
derived IFN-γ secretion due to decreased IL-12p40 production in SOCS3-deficient DCs 
accounts for the increased susceptibility to M. tuberculosis infection of Socs3fl/fl LysM 
cre mice (Fig. 12).  
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Figure 12: Role of SOCS3 in myeloid cells during M. tuberculosis infection. 
SOCS3 increases the secretion of IL-12 and TNF in M. tuberculosis-infected 
macrophages and DCs (1). Infected dendritic cells prime Th1 cells in the draining 
lymph node (2) and in the presence of SOCS3 we found earlier high levels of          
IFN-γ in the lungs (3) activating infected cells.  
 
In line with our results, the increased susceptibility of Socs3fl/fl LysM cre mice to 
T. gondii was due to reduced IL-12 responses that could be restored either by IL-6 
neutralization or by administration of recombinant IL-12276. Since immune defense 
mechanisms to the intracellular T. gondii and intracellular M. tuberculosis resemble 
each other, it is not surprising that we found a similar setting during M. tuberculosis 
infection. Accordingly, in T. gondii–infected Socs3fl/fl LysM cre mice impaired        
IFN-γ secretion by T and NK cells was found276, but unlike M. tuberculosis defense 
mechanisms that mainly rely on T cells, IFN-γ produced by NK cells plays a crucial 
role in protection to T. gondii114,287,288.  
Together with our data, this demonstrates a so far unappreciated role of IL-6 
that, in the absence of SOCS3 in myeloid cells, becomes a potent antagonist of        
IFN-γ−mediated protection. 
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What is the role of SOCS3 in T cells during M. tuberculosis infection in vivo regarding 
the regulation of bacterial loads, cytokine responses and immunopathology? 
 Mice with SOCS3-deficient T cells (Socs3fl/fl lck cre mice) displayed a 
dramatically increased susceptibility to M. tuberculosis infection. In comparison to 
Socs3fl/fl LysM cre mice, SOCS3 deficiency in T cells led to higher bacterial loads in 
the lungs and spleen, increased pathology, and earlier mortality. Transfer of SOCS3-
deficient T cells in Rag1-/- mice did not convey resistance and suppressed protection by 
co-inoculated control T cells. Moreover, absence of SOCS3 in T cells in Leishmania 
major-infected mice increased parasite counts confirming a SOCS3-dependent 
protection mechanism258.   
However, the observed susceptibility to M. tuberculosis seemed to be a 
pathogen-specific mechanism because detected bacterial numbers after BCG infection 
in Socs3fl/fl lck cre and control mice were similar.  Surprisingly, BCG-vaccinated 
Socs3fl/fl lck cre mice showed the same protection to challenge with M. tuberculosis as 
control mice. This suggests that SOCS3 in T cells is not necessarily required for the 
resistance to M. tuberculosis if T cells are primed by BCG-immunization. In contrast to 
our results, Socs3fl/fl lck cre mice showed faster LCMV clearance than infected control 
mice demonstrating a very divergent function of SOCS3 depending on the pathogen270. 
Since we detected higher levels of Socs3 mRNA expression in M. tuberculosis 
than in BCG-infected lungs, we speculated that Socs3 expression levels in T cells might 
be elevated during M. tuberculosis in contrast to BCG infection.  Unexpectedly, we did 
not detect any upregulation of Socs3 mRNA in pulmonary T cells neither after M. 
tuberculosis nor after BCG infection. Our data obtained from mycobacteria-infected 
mice is consistent with earlier observations that describe a down-regulation of SOCS3 
in antigen-stimulated T cells in comparison to naïve T cells250. However, since the 
regulation of SOCS3 expression in T cells during BCG and M. tuberculosis infection is 
comparable, it does not explain the increased susceptibility to M. tuberculosis of 
Socs3fl/fl lck cre mice. 
 The immune responses of Socs3fl/fl lck cre mice were then investigated.  We 
chose 2.5 weeks after M. tuberculosis infection as first examined time point as antigen-
specific T cells were already present in the lungs, but bacterial loads in control and 
Socs3fl/fl lck cre mice were similar. We found that higher levels of IL-17 were secreted 
in response to antigen-specific stimulation of lung homogenates by Socs3fl/fl lck cre 
mice matching previously reported SOCS3-mediated inhibition of Th17 
generation249,254,259. However, no differences in IL-17 secretion were detected after re-
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stimulation of splenocytes from BCG-immunized Socs3fl/fl lck cre and control mice. 
Therefore, the increased IL-17 secretion and susceptibility to M. tuberculosis in 
Socs3fl/fl lck cre mice could be causally associated. The role of IL-17 in resistance to M. 
tuberculosis is controversial and the lack of IL-17 or IL-17R in a low dose model that is 
also applied in our experiments did not impair the ability of mice to control M. 
tuberculosis infection144,145. In contrast, high IL-17 levels may contribute to an 
increased bacterial dissemination and a neutrophil-mediated inflammation that may 
account for the early death and immunopathology of M. tuberculosis-infected Socs3fl/fl 
lck cre mice as described for other susceptible mouse strains55,289,290.  In fact, increased 
neutrophil-derived molecules and necrosis could be observed in M. tuberculosis-
infected Socs3fl/fl lck cre mice.  
Moreover, IFN-γ levels were elevated in Socs3fl/fl lck cre mice already 2.5 
weeks after M. tuberculosis infection and might be explained by the described binding 
of SOCS3 to IL-12Rβ2257. However, increased IFN-γ levels cannot justify the dramatic 
susceptibility to M. tuberculosis of  Socs3fl/fl lck cre mice. Kinjyo et al. reported that 
SOCS3-deficient T cells show enhanced development of Th3 cells that produce anti-
inflammatory cytokines such as IL-10 and TGF-β258. Nevertheless, IL-10 levels were 
not increased in Socs3fl/fl lck cre mice.  
Altogether, additional studies on IL-17 that is increased during M. tuberculosis 
but not during BCG infection in Socs3fl/fl lck cre mice may provide promising insights 
into its role during M. tuberculosis infection.  
 
Which function has gp130 signaling in SOCS3-deficient models in vivo and in vitro 
during mycobacterial infections?  
 SOCS3 inhibits different signaling receptors. We investigated whether SOCS3 
promoted resistance against M. tuberculosis via the regulation of gp130-dependent or 
independent receptor signals.   We found that gp130F/F mice were highly susceptible to 
M. tuberculosis infection, which was at least in part caused by aberrant IL-6 and 
STAT3 responses since gp130F/FIl-6-/- and gp130F/FStat3+/- mice displayed lower 
bacterial loads than gp130F/F mice. Cytokine responses of mycobacteria-infected 
gp130F/F BMM resembled Socs3fl/fl LysM cre BMM with decreased IL-12 and TNF 
levels compared to control cells. Previously, it had been demonstrated that gp130F/F 
BMM alike Socs3fl/fl LysM cre BMM induce reduced TNF and IL-12 levels in response 
to LPS and IL-6 compared to control BMM242. Moreover, we could demonstrate that 
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the reduction of cytokine concentration during mycobacterial infections was IL-6 
dependent since IL-12 and TNF levels in gp130F/F/Il-6-/-  BMM were restored to control 
levels. Accordingly, lower IL-12p40 expression levels were found in the lungs of 
gp130F/F compared to control mice, which were restored in gp130F/FIl-6-/- mice, 
implying that changed IL-6 signaling in the absence of SOCS3 inhibition of gp130 
signaling may account for the increased susceptibility.  
Taken together, we propose that, as in Socs3fl/fl LysM cre mice, delayed T cell 
priming due to impaired IL-12 induction contributes to the susceptibility to M. 
tuberculosis in gp130F/F mice. Similar results were obtained during T. gondii infection 
of gp130F/F mice that showed a transient reduction of IFN-γ serum levels275. Treatment 
of gp130F/F mice with either neutralizing IL-6 antibodies or exogenous IL-12 improved 
parasite control demonstrating that SOCS3 provides similar protection mechanisms by 
modulation of gp130 signaling during T. gondii and M. tuberculosis infection275. 
Interestingly, T cells from gp130F/F mice could transfer protection to Rag1-/- to 
the same extent as transferred control T cells, indicating that the protective SOCS3 
expression in T cells is gp130-independent. Since the susceptibility of gp130F/F to M. 
tuberculosis was significantly higher than of Socs3fl/fl LysM cre and T cells were not 
involved, we suggest that non-hematopoietic cells may also contribute to SOCS3-
mediated control to M. tuberculosis infection, a suggestion that remains to be tested.  
 Altogether, SOCS3 plays a critical and non-redundant role in myeloid and T 
cells during M. tuberculosis infection. Notably, mechanisms of resistance conveyed by 
SOCS3 are different in myeloid and T cells but in both cases necessary to enable a 
proper T cell differentiation.  
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5 SUMMARY 
 
In summary, we define the following roles for SOCS proteins during M. tuberculosis 
infection: 
 
SOCS1 
… reduces IFN-γ induction in response to IL-12 in macrophages. 
… inhibits IFN-γ-mediated growth control during early infection.   
… is a major controller of non-macrophage-mediated inflammation. 
 
 
SOCS2 
… has no influence on mycobacterial growth control. 
 
 
SOCS3 
… in myeloid and T cells reduces susceptibility to infection. 
… in myeloid cells impairs IL-6 dependent reduction of IL-12 and TNF 
secretion and leads to early induction of IFN-γ by CD4+ cells in the 
lungs. 
… in T cells hampers IL-17 and IFN-γ secretion during M. tuberculosis 
infection.  
… is redundant in T cells for M. tuberculosis protection if mice are BCG-
vaccinated. 
… mediates inhibition of gp130-transmitted signals and thereby reduces 
susceptibility that is dependent on IL-6 and STAT3. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
Summarizing the studies on SOCS proteins presented in this thesis, I would like 
to give an evaluation of the role of the different SOCS proteins during mycobacterial 
infections and discuss under which circumstances a modulation of SOCS levels may 
be of importance in controlling the infection. 
 SOCS1 plays a two-faced role during mycobacterial infections. During the 
innate phase, when bacteria replicate in macrophages without any adaptive immunity 
present, SOCS1 suppresses IFN-γ induction by macrophages and therefore enables 
mycobacterial growth. Deletion of SOCS1 could slow down this mycobacterial 
growth but did not lead to complete eradication of the bacteria. Since it has been 
proposed that a fraction of the M. tuberculosis-exposed individuals remain 
uninfected, it would be interesting to determine whether SOCS1 is involved in such 
innate control of infection.  In contrast, SOCS1 expression protected from severe 
inflammation in the lungs without impairing immunity to infection during later stages 
of M. tuberculosis infection. Thus, SOCS1 mimetic peptides may be useful to limit 
immune-mediated pathology in tuberculosis as it was shown in a vaccinia virus 
infection model192. 
 Regarding our data on SOCS2, its role can be addressed as minor or redundant 
during M. tuberculosis infection. Although enhanced Th2 responses were reported in 
the absence of SOCS2, we observed similar bacterial burdens in presence and 
absence of SOCS2 suggesting a well functioning Th1 response. However, it is 
possible that under Th2-stimulating conditions, such as a common co-infection with 
helminths, absence of SOCS2 may further enhance Th2 responses and thereby impair 
M. tuberculosis control.  
  In contrast to SOCS1 and SOCS2, SOCS3 expression by either myeloid or 
lymphoid cells had a central role in controlling M. tuberculosis infection,. Absence of 
SOCS3 in BMM has been described to prolong STAT3 activation in response to IL-6 
that in turn decreased IL-12 and TNF transcription126. The knockdown of STAT3 in 
DCs has been shown to increase cytokine production, antigen-specific T cell 
activation and resistance to IL-10-mediated suppression291. Moreover, increased 
STAT3 activation prevents recognition of tumor cells by the immune system in 
different kinds of cancer and inhibition of STAT3 activation by administration of 
small inhibitory molecules has been shown to impair the growth of cancer cells in 
vitro and in vivo292. Therefore, it would be a promising approach to limit STAT3 
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activation to improve resistance to M. tuberculosis infection by increasing IL-12 
levels and antigen-specific Th1 responses.  However, since STAT3 is unique in its 
capacity to direct anti-inflammatory activities of IL-10 and mice with a knockdown 
for STAT3 in myeloid cells showed a pro-inflammatory phenotype with spontaneous 
development of colitis243, it will be a challenge to keep the balance between pro- and 
anti-inflammatory signals. Additionally, it has to be taken in consideration that a 
knockdown of gp130 in myeloid cells did not improve control of M. tuberculosis 
infection in mice, demonstrating that ablation of all gp130-mediated signals may be 
contraindicated293.  Even considering these aspects, our data convincingly argue for 
further explorations in targeting STAT3 to improve immune control during 
tuberculosis. 
 Since SOCS3 expression in T cells was not required to mount protective 
immunity after BCG-vaccination, it would be of high interest to understand why 
SOCS3 in turn is required for resistance to primary M. tuberculosis infection.  
Furthermore, the high IL-17 levels in the absence of SOCS3 in T cells may have 
contributed to the observed susceptibility since we did not detect any elevated anti-
inflammatory immune responses that could account for increased bacterial growth. 
Understanding the role of these two factors, SOCS3 expression and elevated IL-17 
secretion by T cells during M. tuberculosis infection, may provide important 
information how to achieve protection against M. tuberculosis and thereby how to 
improve vaccine design. Summarizing, we suggest that modulation of SOCS3-
regulated pathways is a promising approach to improve vaccination and the control of 
mycobacterial infections.  
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